Ensem Therapeutics Begins Phase 1/2 Trial of Oral KRAS Inhibitor ETX-929 for Advanced Cancers

0
14
Ron Peck, M.D.

WALTHAM, Mass.–Ensem Therapeutics has begun dosing patients in a Phase 1/2 clinical trial of ETX-929, an investigational oral pan-KRAS inhibitor being developed to treat advanced solid tumors with KRAS alterations.

The Waltham-based biopharmaceutical company said the first-in-human study will evaluate the drug in patients with several types of cancer, including colorectal, pancreatic, non-small cell lung, and gynecologic cancers.

ETX-929 is the third experimental oral inhibitor developed through Ensem’s Kinetic Ensemble platform to enter clinical testing, following ETX-197 and ETX-636.

The treatment is designed to inhibit KRAS, a protein involved in regulating cell growth that is frequently altered in cancer. KRAS mutations can drive tumor growth and are found across multiple cancer types.

Unlike therapies targeting specific KRAS mutations, ETX-929 is designed to inhibit a broad range of KRAS alterations while avoiding interference with the related HRAS and NRAS proteins.

“As one of the most frequently altered oncogenes across cancer types, KRAS represents a major opportunity for medical oncology, and KRAS G12C inhibitors have already become important therapies for patients with that one mutation,” said Ron Peck, M.D., Chief Medical Officer of Ensem.

“By targeting the full range of KRAS alterations while sparing HRAS and NRAS, ETX-929 has the potential to deliver greater efficacy at doses patients can tolerate, building on the promise seen with early pan-RAS inhibitors.”

ETX-929 is designed to inhibit KRAS in both its active and inactive states, including major KRAS mutations and amplified wild-type KRAS.

According to Ensem, preclinical studies demonstrated strong antitumor activity, including tumor regression, along with favorable oral bioavailability across multiple species.

The company said these findings support the potential for relatively low oral doses in patients, although the drug’s safety and effectiveness have not yet been established in humans.

“We designed ETX-929 to set a new standard among pan-KRAS inhibitors,” said Shengfang Jin, Ph.D., President and Chief Executive Officer of Ensem.

“ETX-929 potently inhibits KRAS in both its active (ON) and inactive (OFF) states, across the major KRAS mutations as well as amplified wildtype KRAS. In preclinical studies, it showed a potential best-in-class profile compared with other pan-KRAS inhibitors, with sub-nanomolar in vivo potency, tumor regressions, and good oral bioavailability across species, including non-human primates, supporting low projected oral doses in patients. Following ETX-197 and ETX-636, ETX-929 is the third clinical candidate from our Kinetic Ensemble® platform, and we hold global rights to all of our programs.”

The Phase 1/2 trial is an open-label, multicenter study designed to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of ETX-929.

Researchers will evaluate the treatment both as a standalone therapy and in combination with cetuximab, an approved cancer drug. Additional combination treatment groups may be introduced as the study progresses.

The trial includes dose-escalation and expansion phases intended to identify appropriate dosing levels and evaluate early evidence of clinical activity in patients with advanced KRAS-altered solid tumors.

The study is proceeding under an Investigational New Drug application cleared by the U.S. Food and Drug Administration.

The clinical trial is registered under identifier NCT07912593.

ETX-929 remains an investigational treatment and has not been approved for commercial use.

Leave A Reply

Please enter your comment!
Please enter your name here